Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 13, 231-237
Abstract
Purpose: Intrathecal morphine infusion therapy via a percutaneous port (IMITPP) has been used widely for its relatively low initial cost. However, there is scarce knowledge about IMITPP. In this study, we sought to evaluate efficacy, complications, and the interval required to achieve the cost equivalence of IMITPP in patients with refractory cancer pain in China. Patients and Methods: A retrospective chart review was conducted on cancer patients who had received IMITPP at our hospital between April 2017 and April 2019. Data from the numeric pain rating scale and Karnofsky performance scores, and complications and costs related to IMITPP were collected from medical records. Daily analgesic costs before and after IMITPP were calculated based on the doses of opioids on admission and at discharge, respectively. The doses of systemic opioids before IMITPP were stratified into very high doses [VHD, oral morphine equivalent dose (OMED) > 599 mg/day], high doses (HD, 300 mg/day ≤ OMED ≤ 599 mg/day), and regular doses (RD, OMED < 300 mg/day). Results: Intrathecal morphine infusion therapy via a percutaneous port provided significant pain relief, but impaired activities of daily living in patients with refractory cancer pain. The commonly reported complications included nausea/vomiting and urinary retention, most of which were managed with symptomatic therapies. The median interval required to achieve cost equivalence was 11.44 months. The median intervals of VHD group and HD group were significantly shorter than that of RD group. Conclusion: Intrathecal morphine infusion therapy via a percutaneous port provided effective cancer pain management without causing serious complications. Patients with higher doses of systemic opioids would economically benefit from IMITPP in a shorter time.Keywords
This publication has 28 references indexed in Scilit:
- Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in KoreaYonsei Medical Journal, 2016
- A Cost Utilization Analysis of Intrathecal Therapy for Refractory Cancer Pain: Identifying Factors Associated with Cost BenefitPain Medicine, 2013
- Continuous Intrathecal Morphine Administration for Cancer Pain Management Using an Intrathecal Catheter Connected to a Subcutaneous Injection Port: A Retrospective Analysis of 22 Terminal Cancer Patients in Korean PopulationThe Korean Journal of Pain, 2013
- Characteristics of Distribution of Morphine and Metabolites in Cerebrospinal Fluid and Plasma with Chronic Intrathecal Morphine Infusion in HumansAnesthesia & Analgesia, 2012
- Intrathecal Drug Delivery System (IDDS) for Cancer Pain ManagementAmerican Journal of Hospice and Palliative Medicine®, 2011
- Conversion ratios for opioid switching in the treatment of cancer pain: a systematic reviewPalliative Medicine, 2011
- Prevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnnals of Oncology, 2007
- Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysisJournal of Neurosurgery, 2002
- Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and SurvivalJournal of Clinical Oncology, 2002
- A prospective multicenter assessment of the Edmonton staging system for cancer painJournal of Pain and Symptom Management, 1995